HERMES — Ziltivekimab in Heart Failure
Heart failure with mid-range or preserved ejection fraction and systemic inflammation
Protocol: EX6018-4915
About this study
A Phase 3 randomized, placebo-controlled trial evaluating ziltivekimab, a fully human monoclonal antibody targeting interleukin-6, in patients with heart failure and systemic inflammation. Amavita Research Services is an enrolling site, with Dr. Pedro Martinez-Clark as Principal Investigator.
Sponsor: Novo Nordisk · Principal Investigator: Pedro Martinez-Clark, MD, FACC
Key eligibility
- Adults with heart failure (HFmrEF or HFpEF)
- Evidence of systemic inflammation (e.g., elevated hsCRP)
- On stable guideline-directed medical therapy
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit with our team.
What participation involves
Most studies follow the same general flow: a phone pre-screen, an in-person screening visit, informed consent, baseline testing, the treatment phase, and follow-up visits. Study-related care is provided at no cost. You may withdraw at any time, for any reason.
Note
This page is a plain-language overview. For the official, definitive protocol summary, please refer to ClinicalTrials.gov or speak with our coordinator.